1-1 of 1
John Sweetenham
Close
Sort by
Articles

Recommendation of CHOP-Rituximab/More Intensive Regimen Such as Dose-Adjusted EPOCH-Rituximab for Cyclin D1 Expression in DLBCL

John Sweetenham, MD, FRCP
Journal: The Hematologist
The Hematologist (2011) 8 (2)
https://doi.org/10.1182/hem.V8.2.6302
Published: 2011